PRACTICAL AND PSYCHOLOGICAL DIFFICULTIES EXPERIENCED BY PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR) IN ITALY: PRELIMINARY RESULTS FROM THE TELETHON GUP 15010 STUDY

被引：0

作者：

Magliano, L. ^{[1
]}

Citarelli, G. ^{[1
]}

Obici, L. ^{[2
]}

Sforzini, C. ^{[2
]}

Di Buduo, E. ^{[2
]}

Sabatelli, M. ^{[3
]}

Luigetti, M. ^{[3
]}

Bisogni, G. ^{[3
]}

Grandis, M. ^{[4
]}

Gemelli, C. ^{[4
]}

Fabrizi, G. ^{[5
]}

Cavallaro, T. ^{[5
]}

Pareyson, D. ^{[6
]}

Fenu, S. ^{[6
]}

Santoro, L. ^{[7
]}

Manganelli, F. ^{[7
]}

Mauro, A. ^{[8
]}

Pradotto, L. ^{[9
]}

Antonini, G. ^{[10
]}

Leonardi, L. ^{[10
]}

Vanoli, F. ^{[10
]}

Russo, M. ^{[11
]}

Stancanelli, C. ^{[11
]}

Mazzeo, A. ^{[12
]}

Vita, G. ^{[12
]}

机构：

[1] Univ Campania, Dept Psychol, Caserta, Italy

[2] IRCCS Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Pavia, Italy

[3] Policlin A Gemelli Fdn, Dept Geriatr Neurosci & Orthoped, Rome, Italy

[4] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet & Maternal, Genoa, Italy

[5] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy

[6] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy

[7] Univ Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Naples, Italy

[8] Univ Torino, Dipartimento Neurosci Rita Levi Montalcini, Turin, Italy

[9] IRCCS, Ist Auxol Italiano, Div Neurol & Neuroriabilitaz, Osped S Giuseppe, Oggebbio, VB, Italy

[10] Sapienza Univ Roma, Osped St Andrea, Dip NESMOS, Rome, Italy

[11] Nemo Sud Clin Ctr, Messina, Italy

[12] Univ Messina, Unit Neurol & Neuromuscular Dis, Dept Clin & Expt Med, Messina, Italy

来源：

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2019年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S30 / S30

页数：1

共 50 条

[21] HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Adams, David
Tournev, Ivailo L.
Taylor, Mark S.
Coelho, Teresa
Plante-Bordeneuve, Violaine
Berk, John L.
Gonzalez-Duarte, Alejandra
Gillmore, Julian D.
Low, Soon-Chai
Sekijima, Yoshiki
Obici, Laura
Blakesley, Rick
Arum, Seth
Shilling, Rebecca
Vest, John
Polydefkis, Michael
NEUROLOGY, 2021, 96 (15)
[22] INOTERSEN IMPROVES NORFOLK QUALITY OF LIFE-DIABETIC NEUROPATHY (NORFOLK QOLDN) MEASURES IN PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS IN THE PHASE 3 STUDY NEURO-TTR
Polydefkis, Michael
Cruz, Marcia Waddington
Dyck, Peter
Scheinberg, Morton
Berk, John
Barroso, Fabio
Brannagan, Thomas
Drachman, Brian
Heitner, Stephen
Gorevic, Peter
Monia, Brett
Gertz, Morie
Benson, Merrill
Wang, Annabel
MUSCLE & NERVE, 2018, 58 : S54 - S54
[23] Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study
Pereon, Yann
Adams, David
Camdessanche, Jean-Philippe
Chanson, Jean-Baptiste
Cintas, Pascal
Magy, Laurent
Signate, Aissatou
Sole, Guilhem
Svahn, Juliette
Tard, Celine
Hababou, Cyrla
Attarian, Shahram
ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)
[24] HELIOS-A: 18-MONTH EXPLORATORY CARDIAC RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
Mussinelli, Roberta
Garcia-pavia, Pablo
Gillmore, Julian D.
Kale, Parag
Berk, John L.
Maurer, Mathew S.
Conceicao, Isabel
Dicarli, Marcelo
Solomon, Scott
Chen, Chongshu
Arum, Seth
Vest, John
Grogan, Martha
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
[25] INOTERSEN IMPROVES MODIFIED NEUROPATHY IMPAIRMENT SCORE PLUS 7 (MNIS+7) MEASURES IN PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS IN THE PHASE 3 STUDY NEURO-TTR
Dyck, Peter
Litchy, William
Wang, Annabel
Cruz, Marcia Waddington
Polydefkis, Michael
Scheinberg, Morton
Berk, John
Barroso, Fabio
Brannagan, Thomas
Drachman, Brian
Heitner, Stephen
Gorevic, Peter
Monia, Brett
Gertz, Morie
Benson, Merrill
MUSCLE & NERVE, 2018, 58 : S55 - S55
[26] Long-term efficacy and safety of Inotersen in patients with hereditary transthyretin (hATTR) amyloidosis treated in the open-label extension of the phase-3 study NEURO-TTR
Plante-Bordeneuve, V.
Brannagan, T.
Wang, A.
Coelho, T.
Cruz, M. Waddington
Polydefkis, M.
Dyck, P.
Scheinberg, M.
Berk, J.
Barroso, F.
Adams, D.
Whelan, C.
Merlini, G.
Drachman, B.
Heitner, S.
Conceicao, I.
Schmidt, H.
Vita, G.
Campistol, J.
Gamez, J.
Gorevic, P.
Monia, B.
Benson, M.
Gertz, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 30 - 30
[27] Prevalence and Clinical Characteristics of Patients with Transthyretin Amyloidosis in the United States and Japan: Results from the OverTTuRe Study
Wright, Jason
Alvarez, Christian S.
Hong, Lai San
Jarbrink, Krister
Kumar, Neela
Pao, Christina
Wittbrodt, Eric
Kohsaka, Shun
METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 153
[28] INOTERSEN IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY AND CARDIOMYOPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTR
Maurer, Mathew S.
Heitner, Stephen
Drachman, Brian
Whelan, Carol
Guthrie, Spencer
Tai, Li
Hughes, Steve G.
Monia, Brett P.
Ackermann, Elizabeth J.
Benson, Merrill D.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 658 - 658
[29] Inotersen improves quality of life, polyneuropathy, and cardiomyopathy in patients with hereditary transthyretin amyloidosis: results of the phase 3 study NEURO-TTR
Whelan, C.
Drachman, B.
Heitner, S.
Maurer, M.
Damy, T.
Judge, D.
Monia, B.
Hughes, S.
Kwoh, J.
Jung, B.
Ackermann, E.
Benson, M.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 361 - 361
[30] Impact of patisiran on norfolk QOL-DN in patients with hereditary transthyretin-mediated amyloidosis: results from the cardiac subpopulation in the phase 3 apollo study
Merlini, G.
Solomon, S.
Adams, D.
Coelho, T.
Damy, T.
Mauer, M.
Partisano, A. M.
Chen, J.
Karsten, V.
Vest, J.
Suhr, O. L. E.
Kristen, A.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 383 - 383

← 1 2 3 4 5 →